“…The rising interest in FAV is ascribed to its efficient suppression of dangerous and even lethal infections caused by numerous viruses, such as hemorrhagic fevers, COVID-19, SARS, MERS, rabies, etc. [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ], and by its possible efficacy against viruses, which can be transferred to humans from animals and have a high epidemic potential [ 1 , 4 , 5 , 6 , 17 , 18 ]. Several drug preparations of FAV have been already developed and registered for clinical use (T-705, Avigan, Favilavir, Avifavir, Areplivir, Coronavir) [ 5 , 20 , 21 , 22 ] and many derivatives and analogs are under development (reviewed in [ 46 ]).…”